Literature DB >> 15728620

Diagnosis and treatment of renovascular hypertension: a cost-benefit analysis.

Jean Philippe Bolduc1, Vincent L Oliva, Eric Therasse, Marie-France Giroux, Louis Bouchard, Pierre Perreault, Andrée Cliché, Gilles Soulez.   

Abstract

OBJECTIVE: We sought to evaluate and compare the relative cost-benefit of Doppler sonography, MR angiography, and captopril-enhanced renal scintigraphy as techniques for predicting a patient's clinical response to renal angioplasty.
MATERIALS AND METHODS: Estimations of positive and negative predictive values of baseline and captopril-enhanced renal scintigraphy and Doppler sonography examinations for predicting a favorable outcome after renal angioplasty were based on a previously published prospective study involving 74 patients who underwent this treatment. For gadolinium-enhanced MR angiography, predictive values were calculated from a subpopulation of 57 of these 74 subjects. The value of different combined strategies with these techniques for predicting clinical success after angioplasty was evaluated in this population. The costs of investigation and treatment per improved patient were calculated for each imaging technique and for combined strategies in a hypothetic 1,000-patient population with a 30% prevalence of renal artery stenosis, relying on the diagnostic performance reported in the literature for each technique in detecting renal artery stenosis.
RESULTS: The costs for each improved patient were $12,579 for patients selected on the basis of a positive finding on Doppler sonography (false-negative results = 12/1,000) and $10,149 for patients selected with criteria combining a positive finding on Doppler sonography with a bilateral resistive index of less than 0.75 (false-negative results = 32/1,000). Patient selection based on a positive finding on MR angiography cost $18,119 (false-negative results = 0), whereas the cost of patient selection based on a positive finding on renal scintigraphy was $12,939 (false-negative results = 29/1,000).
CONCLUSION: Doppler sonography is more cost-efficient but less sensitive than MR angiography for identifying patients with renovascular hypertension. MR angiography should be favored in hypertensive patients who are resistant to medical therapy to avoid false-negative examinations.

Entities:  

Mesh:

Year:  2005        PMID: 15728620     DOI: 10.2214/ajr.184.3.01840931

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  7 in total

Review 1.  Atherosclerotic renovascular disease.

Authors:  Sheldon W Tobe; Ellen Burgess; Marcel Lebel
Journal:  Can J Cardiol       Date:  2006-05-15       Impact factor: 5.223

Review 2.  An update on renovascular hypertension.

Authors:  Martin Senitko; Andrew Z Fenves
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

3.  Assessment of the kidneys: magnetic resonance angiography, perfusion and diffusion.

Authors:  Ulrike I Attenberger; John N Morelli; Stefan O Schoenberg; Henrik J Michaely
Journal:  J Cardiovasc Magn Reson       Date:  2011-11-15       Impact factor: 5.364

Review 4.  Evaluation and approach to treatment of renal artery stenosis in patients with diabetic nephropathy.

Authors:  Jose A Silva
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

5.  Glomerular filtration rate measured by (51)Cr-EDTA clearance: Evaluation of captopril-induced changes in hypertensive patients with and without renal artery stenosis.

Authors:  Anna Alice Rolim Chaves; Carlos Alberto Buchpiguel; Jose Nery Praxedes; Luiz Aparecido Bortolotto; Marcelo Tatit Sapienza
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

Review 6.  Ultrasound Doppler renal resistive index: a useful tool for the management of the hypertensive patient.

Authors:  Francesca Viazzi; Giovanna Leoncini; Lorenzo E Derchi; Roberto Pontremoli
Journal:  J Hypertens       Date:  2014-01       Impact factor: 4.844

Review 7.  Renovascular hypertension: an update.

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.